Doxazosin
Product Images NDC 71610-420

5 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4 mg (71610 0420 60)

Bottle Label 4 mg (71610 0420 60)
Doxazosin USP label for 4 mg strength tablets. The label indicates dispensing as 90 tablets, includes storage instructions at controlled room temperature, and states the product is manufactured by Upsher-Smith Laboratories Inc. and packaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also features the NDC 71610-0420-60.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Doxazosin 01)

Chemical Structure (Doxazosin 01)
Chemical structure of the active ingredient Doxazosin as shown in the product labeling for Aphena Pharma Solutions - Tennessee, LLC.*
FDA Label Image

Table 3 (Doxazosin 02)

Table 3 (Doxazosin 02)
A data table and bar graph presenting results from three studies comparing symptom score and maximum flow rate for Doxazosin versus placebo. The table displays mean baseline, mean change, and sample size values. The bar graph illustrates mean changes in maximum flow rate and symptom score for placebo, Doxazosin 4 mg, and 8 mg doses with statistically significant differences noted.*
FDA Label Image

Figure 1 (Doxazosin 03)

Figure 1 (Doxazosin 03)
Two line graphs comparing the effects of Doxazosin tablets and placebo over 14 weeks. The first graph shows mean change in total symptom score from baseline, with Doxazosin showing greater improvement. The second graph shows mean increase in maximum urinary flow rate, with Doxazosin demonstrating a higher increase than placebo. Both graphs include error bars and statistically significant differences marked.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.